Yeast-based universal flu vaccine shows promise
Analysis based on 6 articles · First reported Aug 24, 2026 · Last updated Aug 28, 2026
The potential for a universal flu vaccine could disrupt the seasonal vaccine market, reducing annual demand and shifting production away from egg-based methods. Companies with yeast-based vaccine platforms may see increased interest, while traditional vaccine manufacturers could face long-term competitive pressure.
Researchers at the University of Michigan have developed a process to manufacture flu vaccines in baker's yeast, targeting the conserved M2 protein of influenza A. The vaccine, based on virus-like particles (VLPs) displaying M2, protected mice against multiple influenza strains with 100% efficacy in challenge studies. This approach could offer broader and longer-lasting protection than current seasonal vaccines, potentially making annual shots obsolete. The technology has been licensed to a company developing oral vaccines. The findings were presented at the American Chemical Society Fall 2026 meeting. The research was funded by the United States — National Science Foundation and the University of Michigan College of Engineering.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard